Willy Hugo

Assistant Professor

David Geffen School of Medicine at UCLA

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Willy Hugo is an Assistant Professor at the David Geffen School of Medicine at UCLA, USA. His research primarily focuses on immunology and its implications in cancer therapy, including the mechanisms of immune checkpoint inhibition and the roles of various immune cells in tumor microenvironments. Notable recent publications include studies on TLR agonists in glioma and the impact of IL-21 on effector T cells in autoimmune conditions.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Melissa Lechner

Asst. Professor of Medicine, Onco-Endocrinology Program

David Geffen School of Medicine at UCLA

UNITED STATES

View details

Maureen A. Su

University of California

UNITED STATES

View details

Jeremy G. Reynoso

University of California, Los Angeles

UNITED STATES

View details

Evan Abt

Adjunct Assistant Professor

UCLA

UNITED STATES

View details

Richard Everson

Assistant Professor In Residence

David Geffen School of Medicine at UCLA

UNITED STATES

View details

Jason Whitmire

Professor

University of North Carolina at Chapel Hill

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Willy Hugo

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial

A pathologically expanded, clonal lineage of IL-21–producing CD4+ T cells drives inflammatory neuropathy

<sup>18</sup>F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models

Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors

Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis

Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors

The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy

Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity

Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

Single-cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior

Collaborators (6)

Melissa Lechner

Maureen A. Su

Jeremy G. Reynoso

Evan Abt

Richard Everson

Jason Whitmire

Make your next move.